These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19467991)

  • 1. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome.
    Connor JR; Wang XS; Allen RP; Beard JL; Wiesinger JA; Felt BT; Earley CJ
    Brain; 2009 Sep; 132(Pt 9):2403-12. PubMed ID: 19467991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restless legs syndrome: update on pathogenesis.
    Dauvilliers Y; Winkelmann J
    Curr Opin Pulm Med; 2013 Nov; 19(6):594-600. PubMed ID: 24048084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study.
    Walters AS; Ondo WG; Zhu W; Le W
    J Neurol Sci; 2009 Apr; 279(1-2):62-5. PubMed ID: 19167016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).
    Earley CJ; Connor J; Garcia-Borreguero D; Jenner P; Winkelman J; Zee PC; Allen R
    Sleep Med; 2014 Nov; 15(11):1288-301. PubMed ID: 25201131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial ferritin in the substantia nigra in restless legs syndrome.
    Snyder AM; Wang X; Patton SM; Arosio P; Levi S; Earley CJ; Allen RP; Connor JR
    J Neuropathol Exp Neurol; 2009 Nov; 68(11):1193-9. PubMed ID: 19816198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BTBD9 and dopaminergic dysfunction in the pathogenesis of restless legs syndrome.
    Lyu S; Doroodchi A; Xing H; Sheng Y; DeAndrade MP; Yang Y; Johnson TL; Clemens S; Yokoi F; Miller MA; Xiao R; Li Y
    Brain Struct Funct; 2020 Jul; 225(6):1743-1760. PubMed ID: 32468214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is ferroportin-hepcidin signaling altered in restless legs syndrome?
    Clardy SL; Wang X; Boyer PJ; Earley CJ; Allen RP; Connor JR
    J Neurol Sci; 2006 Sep; 247(2):173-9. PubMed ID: 16759669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients.
    Kim KW; Jhoo JH; Lee SB; Lee SD; Kim TH; Kim SE; Kim YK; Yoon IY
    Eur J Neurol; 2012 Sep; 19(9):1213-8. PubMed ID: 22435397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathophysiology of restless legs syndrome].
    Miyamoto M; Miyamoto T; Iwanami M; Suzuki K; Hirata K
    Brain Nerve; 2009 May; 61(5):523-32. PubMed ID: 19514512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome.
    Connor JR; Boyer PJ; Menzies SL; Dellinger B; Allen RP; Ondo WG; Earley CJ
    Neurology; 2003 Aug; 61(3):304-9. PubMed ID: 12913188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome.
    Lyu S; DeAndrade MP; Mueller S; Oksche A; Walters AS; Li Y
    Behav Brain Res; 2019 Nov; 374():112123. PubMed ID: 31376441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).
    Allen R
    Sleep Med; 2004 Jul; 5(4):385-91. PubMed ID: 15222997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factor pathway activation in restless legs syndrome patients.
    Patton SM; Ponnuru P; Snyder AM; Podskalny GD; Connor JR
    Eur J Neurol; 2011 Nov; 18(11):1329-35. PubMed ID: 21985026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioids protect against substantia nigra cell degeneration under conditions of iron deprivation: a mechanism of possible relevance to the Restless Legs Syndrome (RLS) and Parkinson's disease.
    Sun YM; Hoang T; Neubauer JA; Walters AS
    J Neurol Sci; 2011 May; 304(1-2):93-101. PubMed ID: 21376342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome.
    Allen RP; Earley CJ; Jones BC; Unger EL
    Sleep Med; 2020 Jul; 71():141-148. PubMed ID: 32094092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome.
    Connor JR; Wang XS; Patton SM; Menzies SL; Troncoso JC; Earley CJ; Allen RP
    Neurology; 2004 May; 62(9):1563-7. PubMed ID: 15136682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of iron in restless legs syndrome.
    Allen RP; Earley CJ
    Mov Disord; 2007; 22 Suppl 18():S440-8. PubMed ID: 17566122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update in restless legs syndrome.
    Salas RE; Gamaldo CE; Allen RP
    Curr Opin Neurol; 2010 Aug; 23(4):401-6. PubMed ID: 20581683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease?
    Linke R; Eisensehr I; Wetter TC; Gildehaus FJ; Pöpperl G; Trenkwalder C; Noachtar S; Tatsch K
    Mov Disord; 2004 Oct; 19(10):1158-62. PubMed ID: 15390076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal.
    Earley CJ; Allen RP; Connor JR; Ferrucci L; Troncoso J
    Sleep Med; 2009 Dec; 10(10):1155-7. PubMed ID: 19307154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.